Selpercatinib
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Subsidy Information and Financing Scheme
No
Active ingredient: Selpercatinib
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
[NR] The Ministry of Health’s Drug Advisory Committee has not recommended selpercatinib for inclusion on the MOH List of Subsidised Drugs for treating adult patients with locally advanced or metastatic non-small-cell lung cancer with a rearranged during transfection (RET) gene fusion. The decision was based on selpercatinib being unlikely to represent an acceptable use of healthcare resources at the price proposed by the company.
Clinical indication, subsidy class and MediShield Life claims eligibility for selpercatinib are provided in the Annex.
The Ministry of Health’s Drug Advisory Committee has recommended:
Selpercatinib 40 mg and 80 mg capsules and tablets as monotherapy for:
patients 12 years of age and older with advanced or metastatic medullary thyroid cancer with a rearranged during transfection (RET) mutation who require systemic therapy; and
patients 12 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
in view of clinical need, and acceptable clinical effectiveness, safety, and pricing proposal by the company.
Funding status
[R] Selpercatinib 40 mg and 80 mg capsules and tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications from 1 September 2026.
Clinical indications, subsidy class and MediShield Life claims eligibility for selpercatinib are provided in the Annex.
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals (opens in new tab) or Polyclinics (opens in new tab) for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Capsule 40 mg |
|
Tablet, Film Coated 40 mg |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch (opens in new tab). The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch (opens in new tab) for the most updated product information. |
Oral
* Clinical information is available for this product.